Reuters logo
BRIEF-Theratechnologies partner Taimed submits biologics license application for Ibalizumab
May 4, 2017 / 1:19 AM / 7 months ago

BRIEF-Theratechnologies partner Taimed submits biologics license application for Ibalizumab

May 3 (Reuters) - Theratechnologies Inc

* Theratechnologies partner submits biologics license application for HIV Monoclonal Antibody and long-acting investigational antiretroviral Ibalizumab

* Taimed has requested priority review for application Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below